Siyaram Pandey
University of Windsor, Canada
Title: Workshop
Water soluble Nano-miceller formulation of Ubisol Q10 halts progression of neurodegenerative diseases and cellular aging
Biography
Biography: Siyaram Pandey
Abstract
Risk of neurodegenerative diseases increase as we age. There has been an exponential increase in the number patients diagnosed with Alzheimer’s and Parkinson’s disease as number of elderly increases. Although the etiological factors triggering AD and PD are very different, they ultimately bring about neuronal death which is, most likely, executed by a common mechanism(s). Currently, there are no effective treatments to halt the progression of these diseases and assist in their management. We have used cellular, and animal models (both rat and transgenic mice) of PD and AD to evaluate neuroprotective effects of water soluble Coq10. Recently we have reported unprecedented effectiveness of Ubisol-Q10,(US Patent No. 6,045,826, developed at NRC) at a very low dose of 6 mg/kg/day as an inhibitor of progressive Parkinsonian neurodegeneration in rodent models of disease. Oral intake of Ubisol-Q10 blocked the neurodegenerative processes activated by either MPTP or Paraquat. The formulation contains CoQ10 and PEG-α-tocopherol forming jointly water- soluble nanomicelles. We have confirmed bioavailability of this formulation in brain. A comprehensive behavioral analysis of transgenic animals fed with this formulation indicated significant improvement in motor activity in PD and long term memory and emotional reactivity in AD models compared to untreated animals. These results were complemented with histochemical analysis that indicated significant protection of neurons in substantia niagra region and lower amyloid beta burden in respective models. This treatment leads to the stabilization mitochondrial functions, decrease of oxidative stress in neuronal cells and triggers an increase in neurotrophic factors from surrounding supporting cells such as microglia and astroglial cells. Thus Ubisol Q10 could offers a treatment that could halt the progression of disease in AD and PD patients. This work was supported by CIHR and Michael J. Fox Foundation and a donation from Szecsei Family in Windsor